Abstract
Canine hemangiopericytoma (CHP) is characterized by frequent local recurrence and increased invasiveness. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis in tumors. The aim of the present study was to investigate the effect of a single dose of bevacizumab on a xenograft model of CHP. VEGF protein was secreted from cultured CHP cells and interacted with bevacizumab. Bevacizumab treatment suppressed tumor growth by inhibiting tumor angiogenesis, whereas no significant differences were observed in the proliferation index and apoptosis rates of treated and untreated mice. Thus, bevacizumab had antitumor effects in a xenograft model of CHP.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage*
-
Angiogenesis Inhibitors / pharmacology*
-
Animals
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antibodies, Monoclonal, Humanized / pharmacology*
-
Bevacizumab
-
Disease Models, Animal
-
Dog Diseases*
-
Dogs
-
Hemangiopericytoma / blood supply*
-
Hemangiopericytoma / genetics
-
Hemangiopericytoma / pathology
-
Hemangiopericytoma / veterinary*
-
Male
-
Mice
-
Mice, Inbred NOD
-
Neoplasm Transplantation
-
Neovascularization, Pathologic / genetics*
-
Transplantation, Heterologous
-
Tumor Cells, Cultured
-
Vascular Endothelial Growth Factor A / physiology*
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Vascular Endothelial Growth Factor A
-
Bevacizumab